Phase II trial of second-line erlotinib and digoxin in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Kayali, F. [1 ]
Janjua, M. A. [1 ]
Laber, D. A. [1 ]
Miller, D. M. [1 ]
Day, J. M. [1 ]
Kloecker, G. H. [1 ]
机构：
[1] Univ Louisville, Louisville, KY 40292 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19077
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Biweekly paclitaxel as second-line treatment in advanced non-small cell lung-cancer (NSCLC). A phase II study of the Lung Cancer Galician Group
    Vazquez-Estevez, S.
    Firvida, J.
    Huidobro, G.
    Leon, L.
    Lazaro, M.
    Salgado, M.
    Mel, J.
    Grande, C.
    Perez, E.
    Campos, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] SECOND LINE ERLOTINIB IN NON-SMALL CELL LUNG CANCER: A LOCAL EXPERIENCE
    Smith, C. F.
    Garcia-Alonso, Angel
    Drury, G.
    Gostage, A.
    Smith, N.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1180 - S1181
  • [43] Gemcitabine as second-line treatment for advanced non-small-cell lung cancer:: A phase II trial
    Crinò, L
    Mosconi, AM
    Scagliotti, G
    Selvaggi, G
    Novello, S
    Rinaldi, M
    Della Giulia, M
    Gridelli, C
    Rossi, A
    Calandri, C
    De Marinis, F
    Noseda, M
    Tonato, M
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2081 - 2085
  • [44] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Phase II clinical trial of kahalalide F (KF) as a second line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Provencio, Mariano
    Izquierdo, Angel
    Vinolas, Nuria
    Paz-Ares, Luis
    Feliu, Jaime
    Constenla, Manuel
    de las Heras, Begona
    Erustes, Mercedes
    Izquierdo, Miguel A.
    Rosell, Rafael
    ANNALS OF ONCOLOGY, 2006, 17 : 225 - 225
  • [46] ZD0473 as second-line therapy in non-small cell lung cancer: A Phase II study
    Treat, J
    Huang, C
    Damanjov, N
    Jahenzeb, M
    Edelman, M
    Koehler, M
    LUNG CANCER: CURRENT TOPICS, 2001, : 341 - 344
  • [47] Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC)
    Govindan, R.
    Zergebel, C.
    Saito, K.
    Schiller, J. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [49] Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer
    Veslemes, M
    Antoniou, D
    Georgatou, N
    Giamboudakis, P
    Dimitroulis, J
    Katis, K
    Stathopoulos, GP
    ANTICANCER RESEARCH, 2005, 25 (04) : 2991 - 2996
  • [50] Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer
    Hoang, Tien
    Kim, KyungMann
    Merchant, Joseph
    Traynor, Anne M.
    McGovern, James
    Oettel, Kurt R.
    Sanchez, Fredrico A.
    Ahuja, Harish G.
    Hensing, Thomas A.
    Larson, Martha
    Schiller, Joan H.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 218 - 225
12345